Logo

BioSkryb: Sean Keohane

Apr 02, 2021

BioSkryb has appointed Sean Keohane as senior vice president of commercial operations to spearhead commercialization of the company's ResolveDNA products for singe-cell whole-genome amplification. Keohane previously was VP of US marketing and sales at Numares. He has also previously held a variety of sales, marketing, and management positions at companies such as Molecular Devices, Thermo Fisher Scientific, Qiagen, Ciphergen Biosystems, Ventana Medical Systems, and Roche.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.